$IRWD
Ironwood Pharmaceuticals Inc Stock $irwd

$irwd Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000110465913078311 Filed on October 28, 2013

Income Statement

Concept	2013 Q3	2012 Q4	2012 Q3
Revenue	$4.932M	$26.98M	$96.41M
YoY Change	-94.88%	-16.09%	689.11%
Cost Of Revenue	$2.021M	$1.000M	$0.00
YoY Change
Gross Profit	$2.911M	$26.00M	$96.40M
YoY Change	-96.98%	-19.25%
Gross Profit Margin	59.02%	96.37%	99.99%
Selling, General & Admin	$30.26M	$41.60M	$22.85M
YoY Change	32.47%	177.33%	109.6%
% of Gross Profit	1039.64%	160.0%	23.7%
Research & Development	$23.02M	$28.30M	$23.45M
YoY Change	-1.86%	16.94%	2.39%
% of Gross Profit	790.66%	108.85%	24.33%
Depreciation & Amortization	$3.000M	$2.800M	$3.000M
YoY Change	0.0%	3.7%	30.43%
% of Gross Profit	103.06%	10.77%	3.11%
Operating Expenses	$53.28M	$69.90M	$48.81M
YoY Change	9.17%	78.32%	44.25%
Operating Profit	-$56.55M	-$43.90M	$47.61M
YoY Change	-218.78%	527.14%	-320.24%
Interest Expense	$5.265M	$0.00	$14.00K
YoY Change	37507.14%	-100.0%	-12.5%
% of Operating Profit			0.03%
Other Income/Expense, Net	-$5.224M	$45.00K	$27.00K
YoY Change	-19448.15%	-22.41%	-97.26%
Pretax Income	-$61.80M	-$43.90M	$47.64M
YoY Change	-229.74%	527.14%	-330.9%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$61.78M	-$43.90M	$47.64M
YoY Change	-229.68%	527.14%	-331.24%
Net Earnings / Revenue	-1252.53%	-162.71%	49.41%
Basic Earnings Per Share	-$0.51	-$0.41	$0.44
Diluted Earnings Per Share	-$0.51	-$0.41	$0.42
COMMON SHARES
Basic Shares Outstanding	120.8M shares		107.3M shares
Diluted Shares Outstanding	120.8M shares		114.3M shares

Balance Sheet

Concept	2013 Q3	2012 Q4	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$242.4M	$168.2M	$193.3M
YoY Change	25.4%	2.56%	10.39%
Cash & Equivalents	$144.5M	$136.7M	$125.9M
Short-Term Investments	$97.90M	$31.50M	$67.50M
Other Short-Term Assets	$9.800M	$8.000M	$7.900M
YoY Change	24.05%	175.86%	172.41%
Inventory	$20.56M	$6.699M	$965.0K
Prepaid Expenses
Receivables	$125.0K	$457.0K	$169.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$275.8M	$184.4M	$202.3M
YoY Change	36.31%	10.07%	13.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$37.23M	$37.54M	$36.47M
YoY Change	2.09%	11.63%	10.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.639M	$283.0K	$54.00K
YoY Change	8490.74%	105.07%	-99.31%
Total Long-Term Assets	$50.02M	$45.47M	$44.17M
YoY Change	13.23%	9.8%	8.53%
TOTAL ASSETS
Total Short-Term Assets	$275.8M	$184.4M	$202.3M
Total Long-Term Assets	$50.02M	$45.47M	$44.17M
Total Assets	$325.8M	$229.9M	$246.5M
YoY Change	32.18%	10.02%	12.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.436M	$14.22M	$2.652M
YoY Change	-8.14%	120.9%	10.5%
Accrued Expenses	$18.80M	$21.17M	$16.69M
YoY Change	12.65%	90.35%	-1.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.100M	$300.0K	$300.0K
YoY Change	266.67%	50.0%	50.0%
Total Short-Term Liabilities	$39.70M	$54.94M	$35.58M
YoY Change	11.59%	-15.65%	-49.78%
LONG-TERM LIABILITIES
Long-Term Debt	$178.1M	$300.0K	$400.0K
YoY Change	44425.0%	-25.0%	-20.0%
Other Long-Term Liabilities	$1.653M	$992.0K	$28.50M
YoY Change	-94.2%	-97.05%	-19.03%
Total Long-Term Liabilities	$1.653M	$992.0K	$28.90M
YoY Change	-94.28%	-97.08%	-19.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$39.70M	$54.94M	$35.58M
Total Long-Term Liabilities	$1.653M	$992.0K	$28.90M
Total Liabilities	$41.35M	$55.93M	$64.40M
YoY Change	-35.79%	-43.56%	-39.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$725.8M	-$505.0M	-$461.2M
YoY Change	57.39%	16.8%
Common Stock	$809.9M	$649.0M	$643.2M
YoY Change	25.93%	19.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$84.21M	$144.1M	$182.1M
YoY Change
Total Liabilities & Shareholders Equity	$325.8M	$229.9M	$246.5M
YoY Change	32.18%	10.02%	12.32%

Cashflow Statement

Concept	2013 Q3	2012 Q4	2012 Q3
OPERATING ACTIVITIES
Net Income	-$61.78M	-$43.90M	$47.64M
YoY Change	-229.68%	527.14%	-331.24%
Depreciation, Depletion And Amortization	$3.000M	$2.800M	$3.000M
YoY Change	0.0%	3.7%	30.43%
Cash From Operating Activities	-$58.00M	-$22.40M	$39.00M
YoY Change	-248.72%	190.91%	-253.54%
INVESTING ACTIVITIES
Capital Expenditures	-$1.000M	-$3.400M	-$3.600M
YoY Change	-72.22%	-8.11%	620.0%
Acquisitions
YoY Change
Other Investing Activities	-$17.10M	$35.70M	$2.800M
YoY Change	-710.71%	22.68%	-93.93%
Cash From Investing Activities	-$18.10M	$32.20M	-$600.0K
YoY Change	2916.67%	25.78%	-101.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.000M	1.100M	500.0K
YoY Change	100.0%	83.33%	-16.67%
NET CHANGE
Cash From Operating Activities	-58.00M	-22.40M	39.00M
Cash From Investing Activities	-18.10M	32.20M	-600.0K
Cash From Financing Activities	1.000M	1.100M	500.0K
Net Change In Cash	-75.10M	10.90M	38.90M
YoY Change	-293.06%	-41.08%	87.92%
FREE CASH FLOW
Cash From Operating Activities	-$58.00M	-$22.40M	$39.00M
Capital Expenditures	-$1.000M	-$3.400M	-$3.600M
Free Cash Flow	-$57.00M	-$19.00M	$42.60M
YoY Change	-233.8%	375.0%	-271.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	us-gaap	Assets Current AssetsCurrent	275826000	USD
CY2013Q3	us-gaap	Assets Assets	325843000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	14217000	USD
CY2012Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	7509000	USD
CY2012Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	5664000	USD
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20295063	shares
CY2013Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2012Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2013Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	97919000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	31523000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	19000	USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	6000	USD
CY2012	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	1000	USD
CY2013Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	97938000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	261000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	2735000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3381000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	54938000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	39701000	USD
	irwd	Available For Sale Securities Debt Maturity Period Range High AvailableForSaleSecuritiesDebtMaturityPeriodRangeHigh	P1Y
CY2013Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	4	item
CY2012Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	3	item
CY2012Q4	irwd	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions For More Than Twelve Months AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsForMoreThanTwelveMonths	0	item
CY2013Q3	irwd	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions For More Than Twelve Months AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsForMoreThanTwelveMonths	0	item
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	3000000	USD
CY2013Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	4200000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
CY2013Q3	us-gaap	Inventory Net InventoryNet	20561000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	6699000	USD
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13114000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14594000	USD
CY2013Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1393000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1031000	USD
CY2013Q3	us-gaap	Interest Payable Current InterestPayableCurrent	855000	USD
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3438000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5546000	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18800000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21171000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5199000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5135000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15291000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12912000	USD
	dei	Entity Registrant Name EntityRegistrantName	IRONWOOD PHARMACEUTICALS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001446847
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	136700000	USD
CY2012Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	31528000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	457000	USD
CY2012Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	1030000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8026000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	184440000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	7647000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37537000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	283000	USD
CY2012Q4	us-gaap	Assets Assets	229907000	USD
CY2012Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	308000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	11593000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	18024000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	992000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	174650000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	229907000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	84209000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	325843000	USD
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	648955000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-505016000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	144052000	USD
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q3	us-gaap	Revenues Revenues	96413000	USD
	us-gaap	Revenues Revenues	123265000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23453000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	85201000	USD
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22846000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	59264000	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	48805000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	152127000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	47608000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-28862000	USD
CY2013Q3	us-gaap	Cost Of Revenue CostOfRevenue	2021000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	6670000	USD
CY2013Q3	irwd	Collaboration Expense CollaborationExpense	6182000	USD
	irwd	Collaboration Expense CollaborationExpense	42074000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-56551000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	61483000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	223114000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-205264000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	14000	USD
	us-gaap	Interest Expense InterestExpense	41000	USD
CY2012Q3	us-gaap	Investment Income Net InvestmentIncomeNet	41000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	134000	USD
CY2012Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	27000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.44
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.42
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28769000	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-61775000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-220826000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	16000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	47651000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28768000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	20000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61755000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	14000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-220812000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8522000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-20000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12912000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-840000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1324000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-470000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	500000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4978000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	965000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-84000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3311000	USD
	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-856000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-35509000	USD
	irwd	Increase Decrease In Deferred Rent Payables IncreaseDecreaseInDeferredRentPayables	-2256000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47174000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	661000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-231277000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	60896000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	69335000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10595000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	9000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2147000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73354000	USD
	irwd	Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock	2881000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	203000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	87906000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	312383000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	175000000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	38585000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	7717000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	7752000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87282000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125867000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144452000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114140821	shares
CY2013Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	82661000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	74517000	USD
CY2013Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	45430000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36980000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37231000	USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107266823	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106036522	shares
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	114337327	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106036522	shares
CY2013Q3	us-gaap	Profit Loss ProfitLoss	-61775000	USD
CY2012Q3	us-gaap	Profit Loss ProfitLoss	47635000	USD
	us-gaap	Profit Loss ProfitLoss	-220826000	USD
	us-gaap	Profit Loss ProfitLoss	-28769000	USD
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	120768893	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114140821	shares
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	120768893	shares
CY2013Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	97938000	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	125000	USD
CY2013Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	2961000	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9789000	USD
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	8147000	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4639000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2436000	USD
CY2013Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	5789000	USD
CY2013Q3	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	3711000	USD
CY2013Q3	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	1115000	USD
CY2013Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	2776000	USD
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5074000	USD
CY2013Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	3427000	USD
CY2013Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9519000	USD
CY2013Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12684000	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1653000	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	809911000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-725842000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	19000	USD
CY2013Q3	us-gaap	Revenues Revenues	4932000	USD
	us-gaap	Revenues Revenues	17850000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23016000	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30264000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	20000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79862000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	94508000	USD
CY2012Q3	irwd	Collaboration Expense CollaborationExpense	2506000	USD
	irwd	Collaboration Expense CollaborationExpense	7662000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	5265000	USD
CY2013Q3	us-gaap	Investment Income Net InvestmentIncomeNet	41000	USD
CY2013Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5224000	USD
	us-gaap	Interest Expense InterestExpense	15704000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	142000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15562000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	14000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8647000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15291000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1084000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1599000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3632000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10347000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-120000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-13867000	USD
	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-1953000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3647000	USD
	irwd	Increase Decrease In Deferred Rent Payables IncreaseDecreaseInDeferredRentPayables	-2033000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	207307000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	139827000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5874000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	137766000	USD
	irwd	Proceeds From Stock Options Exercised And Essp And Issuance Of Restricted Stock ProceedsFromStockOptionsExercisedAndESSPAndIssuanceOfRestrictedStock	7833000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	499000	USD
CY2013Q3	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	300000	USD
CY2013Q3	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	1200000	USD
CY2013Q3	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	1200000	USD
CY2013Q3	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	2100000	USD

Files In Submission

Name	View Source	Status
0001104659-13-078311-index-headers.html	Edgar Link	pending
0001104659-13-078311-index.html	Edgar Link	pending
0001104659-13-078311.txt	Edgar Link	pending
0001104659-13-078311-xbrl.zip	Edgar Link	pending
a13-19467_110q.htm	Edgar Link	pending
a13-19467_1ex31d1.htm	Edgar Link	pending
a13-19467_1ex31d2.htm	Edgar Link	pending
a13-19467_1ex32d1.htm	Edgar Link	pending
a13-19467_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
irwd-20130930.xml	Edgar Link	completed
irwd-20130930.xsd	Edgar Link	pending
irwd-20130930_cal.xml	Edgar Link	unprocessable
irwd-20130930_def.xml	Edgar Link	unprocessable
irwd-20130930_lab.xml	Edgar Link	unprocessable
irwd-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRWD
Ironwood Pharmaceuticals Inc Stock $irwd

2013 Q3 Form 10-Q Financial Statement

#000110465913078311 Filed on October 28, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD Ironwood Pharmaceuticals Inc Stock $irwd

2013 Q3 Form 10-Q Financial Statement

#000110465913078311 Filed on October 28, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD
Ironwood Pharmaceuticals Inc Stock $irwd